Gehen Sie mit der App Player FM offline!
Podcasts, die es wert sind, gehört zu werden
GESPONSERT
Zanubrutinib for the Treatment of Waldenstrom's Macroglobulinemia
Manage episode 321676738 series 2812899
In this episode of our podcast, we discuss the use of zanubrutinib for the treatment of Waldenstrom’s Macroglobulinemia. Our episode discusses data from the Phase 3 ASPEN trial, comparing the efficacy and safety of zanubrutinib with ibrutinib in these patients.
Our Guests
Our first guest, Dr. Constantine Tam, is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. He is also the lead author on the ASPEN trial, and provides a detailed look at the key data from this study.
We are then joined by Dr. Carolyn Owen, an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. Dr. Owen discusses the potential impact of the data from the ASPEN trial on Canadian clinical practice. And how zanubrutinib may fit into the Canadian treatment algorithm for Waldenstrom’s Macroglobulinemia.
This podcast episode was sponsored by Beigene Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
68 Episoden
Manage episode 321676738 series 2812899
In this episode of our podcast, we discuss the use of zanubrutinib for the treatment of Waldenstrom’s Macroglobulinemia. Our episode discusses data from the Phase 3 ASPEN trial, comparing the efficacy and safety of zanubrutinib with ibrutinib in these patients.
Our Guests
Our first guest, Dr. Constantine Tam, is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. He is also the lead author on the ASPEN trial, and provides a detailed look at the key data from this study.
We are then joined by Dr. Carolyn Owen, an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. Dr. Owen discusses the potential impact of the data from the ASPEN trial on Canadian clinical practice. And how zanubrutinib may fit into the Canadian treatment algorithm for Waldenstrom’s Macroglobulinemia.
This podcast episode was sponsored by Beigene Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
68 Episoden
Alle Folgen
×1 Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape 17:37
1 LIVE FROM ASH 2023: Isa-CYBORD induction chemotherapy in newly diagnosed, transplant eligible MM 16:58
1 First-line treatment strategies for the management of la/mUC: S2 Ep 5 - ESMO 2023: Discussion on 1L LA/mUC 32:28
Willkommen auf Player FM!
Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.